180146-78-5

Basic information

• Product Name: Benzeneacetonitrile, 4-amino-2-fluoro- (9CI)
• Synonyms: Benzeneacetonitrile, 4-amino-2-fluoro- (9CI)
• CAS NO: 180146-78-5
• Molecular Formula: C₈H₇FN₂
• Molecular Weight: 150.1529832
• Product Categories: HALIDE;AMINEPRIMARY
• Mol File: 180146-78-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzeneacetonitrile, 4-amino-2-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, 4-amino-2-fluoro- (9CI)(180146-78-5)
• EPA Substance Registry System: Benzeneacetonitrile, 4-amino-2-fluoro- (9CI)(180146-78-5)

Safety Data

• Hazardous Substances Data: 180146-78-5(Hazardous Substances Data)

Upstream product

• 853910-00-6 2-(2-difluoro-4-nitrophenyl)acetonitrile 
• 180146-77-4 N-(4-cyanomethyl-3-fluorophenyl)phthalimide 

Downstream Products

• 180146-79-6 4-(2-aminoethyl)-3-fluoroaniline 

Relevant articles and documents

1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The invention relates to imidazoquinolines of formula (I) for use in the treatment of protein kinase dependent diseases; pharmaceutical preparations comprinsing an imidazoquinoline, especially for the treatment of a pretein kinase dependent disease; novel imidazoquinolines; and a process for the preparation of the novel imidazoquinilines.

1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.

Aniline derivatives possessing an inhibitory effect of nitric oxide synthase

Compounds represented by the general formula (1): ? (where R1is SR6or NR7R8, where R6is typically an alkyl group having 1-6 carbon atoms, R7is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2and R3are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3and Y4which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof. The compounds possess a potent nitric oxide synthase inhibiting activity and are useful as therapeutics of cerebrovascular diseases.